172939-06-9

Upstream product

• 109-80-8 1.3-propanedithiol 

Downstream Products

• 172939-07-0 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-4-fluoro-L-ribose propane-1,3-diyl dithioacetal 
• 172939-14-9 1-O-acetyl-3,4-di-O-benzyl-2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)-α-L-talopyranose 
• 172939-09-2 6-O-acetyl-3,4-di-O-benzyl-1,5-dideoxy-1,1,1,5-tetrafluoro-L-altritol 
• 173008-85-0 6-O-acetyl-3,4-di-O-benzyl-1,5-dideoxy-1,1,1,5-tetrafluoro-L-allitol 
• 172939-11-6 3,4-di-O-benzyl-2,6-dideoxy-2,6,6,6-tetrafluoro-α-L-talopyranose 
• 172939-10-5 3,4-di-O-benzyl-1,5-dideoxy-1,1,1,5-tetrafluoro-L-altritol 
• 173008-86-1 3,4-di-O-benzyl-1,5-dideoxy-1,1,1,5-tetrafluoro-L-allitol 
• 172939-08-1 5-O-acetyl-2,3-di-O-benzyl-4-deoxy-4-fluoro-aldehydo-L-ribose 

Relevant academic research and scientific papers

Synthesis and antitumor activity of 7-O-[2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)-α-L-talopyranosyl]-daunomycinone and -adriamycinone

7-O-[2,6-Dideoxy-2-fluoro-5-C-(trifluoromethyl)-α-L-talopyranosyl]-daunomycinone and -adriamycinone have been prepared by the coupling of 3,4-di-O-acetyl-2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)-α-L-talopyranosyl iodide with daunomycinone. The key steps in this synthesis are the regioselective fluorination of methyl α-D-lyxopyranoside to give the 4-deoxy-4-fluoro-β-L-ribopyranoside and the C-trifluoromethylation of the aldehydo-L-ribose derivative to give the 1,1,1-trifluoro-5-monofluoro-L-altritol derivative. Antitumor activities of the synthetic products were compared with those for the 2'-deoxy-2'-fluoro and 2',6'-dideoxy-5'-C-trifluoromethyl analogs. Copyright (C) 1999 Elsevier Science Ltd.

Anthracycline derivative having a trifluoromethylated sugar

Novel anthracycline derivatives have now been produced, which exhibit higher antitumor activities and lower toxicities than those of daunomycin, adriamycin etc. that have been clinically used as anticancer agents. That is, a daunomycinone or adriamycinone

Fluorine-containing anthracycline derivatives having hydroxyl groups(s) mono- or di-o-aminoalkanoylated in the sugar moiety thereof

To provide novel fluorine-containing anthracycline derivatives having high antitumor activities and a solubility in water, there have now been synthesized a 7-O-(2,6-dideoxy-2-fluoro-3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-α-L-talopyranosyl)daunomycinone or -adriamycinone of general formula (I) shown below, as well as a 7-O-(3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-2,6-dideoxy-2,6,6,6-tetrafluoro-α-L-talopyranosyl- or -2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone of general formula (II) shown below: General formula (I) STR1 General formula (II) STR2 wherein either one or both of A1 and A2 is or are an α-amino acid residue or an ω-amino acid residue and T denotes a fluorine or hydrogen atom. The novel fluorine-containing anthracycline derivatives of general formulae (I) and (II) are highly active against tumors and soluble in water, and they are useful as antitumor agents administrable in the form of injectable solution.